January 27, 2023 01:11 PM ESTUpdated 01:52 PM
R&D
Pharma
FDA+

FDA ap­proves an­oth­er in­di­ca­tion for Keytru­da, this time in the ad­ju­vant NSCLC set­ting

Tyler Patchen

News Reporter

Mer­ck’s block­buster can­cer treat­ment Keytru­da has been hand­ed an­oth­er in­di­ca­tion by the FDA.

The US reg­u­la­tor an­nounced on Thurs­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

A service from the Financial Times